Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL

Toxicology and Applied Pharmacology
Ida Franiak-PietrygaMaciej Borowiec

Abstract

Cancer nanotherapeutics have shown promise in resolving some of the limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, and low therapeutic indices, Among the various nanoparticles that are available, dendrimers, highly branched macromolecules with a specific size and shape, are one of the most promising ones. In this preliminary study, we tested the anti-tumor activity of maltotriose-modified fourth-generation poly(propylene imine) glycodendrimers (PPI-G4-M3) in vivo in the subcutaneous MEC-1 xenograft model of human chronic lymphocytic leukemia (CLL) in NOD scid gamma mice. Fludarabine was used for model validation and as a positive treatment control. The anti-tumor response was calculated as tumor volume, tumor control ratio, and tumor growth inhibition. The study showed that PPI-G4-M3 inhibited subcutaneous tumor growth more efficiently than fludarabine. The anti-tumor response was dose-dependent. Cationic PPI-G4-M3 showed the highest anti-tumor activity but also higher toxicity than the neutral dendrimers and fludarabine. These first promising results warrant further studies in the optimization of dendrimers charge, dose, route and schedule of admin...Continue Reading

References

May 18, 2005·Leukemia Research·Severine LoiselChristian Berthou
Nov 4, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Sonke Svenson
Dec 23, 2008·Chemical Reviews·Rakesh Kumar TekadeNarendra Kumar Jain
Jun 9, 2009·Journal of Biophotonics·Msaukiranji MkandawireJörg Opitz
Dec 19, 2009·Blood·Maria Teresa Sabrina BertilaccioPaolo Ghia
Aug 20, 2010·Journal of Biopharmaceutical Statistics·Jianrong Wu
Sep 30, 2010·Chemical Society Reviews·Meredith A Mintzer, Mark W Grinstaff
Oct 7, 2011·Journal of Biomedical Materials Research. Part a·Barbara ZiembaBarbara Klajnert
Mar 1, 2012·Journal of Physiology and Biochemistry·Karol CiepluchWiesława Agnieszka Fogel
May 19, 2012·Biopolymers·Barbara ZiembaBarbara Klajnert
May 25, 2012·Journal of Biomedical Materials Research. Part a·Barbara ZiembaBarbara Klajnert
Jun 7, 2013·Clinical Pharmacology and Therapeutics·J A DiMasiA Malins
Mar 25, 2014·Current Opinion in Genetics & Development·Sadna BudhuTaha Merghoub
Nov 8, 2014·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Dandan LuoJonathan F Lovell
Dec 20, 2014·Drug Discovery Today·Miguel López-Lázaro
Jan 13, 2015·Cancer Informatics·Gregory HatherArijit Chakravarty
Oct 30, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Natalia WrońskaKatarzyna Lisowska
Mar 19, 2016·International Journal of Biological Macromolecules·Ida Franiak-PietrygaMaciej Borowiec
Dec 21, 2016·Macromolecular Bioscience·Ida Franiak-PietrygaMaciej Borowiec
Jan 17, 2017·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Michał Gorzkiewicz, Barbara Klajnert-Maculewicz
Feb 10, 2017·Drug Design, Development and Therapy·Othman Al-SawafValentin Goede
Mar 30, 2017·European Journal of Medicinal Chemistry·Serge MignaniThierry Cresteil
Aug 21, 2018·Toxicology and Applied Pharmacology·Ida Franiak-PietrygaMaciej Borowiec

❮ Previous
Next ❯

Citations

Nov 15, 2020·Drug and Chemical Toxicology·Ida Franiak-PietrygaMaciej Borowiec
Apr 30, 2021·Drug and Chemical Toxicology·Barbara ZiembaIda Franiak-Pietryga
Jun 18, 2021·International Journal of Nanomedicine·Khaled S AllemailemAmjad Ali Khan

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.